截止2020年10月08日22時11分Mirati Therapeutics Inc.（MRTX）最新價180.9100，漲跌額0.7400，漲跌幅0.41%，昨收180.1700，今開182.4400，最高182.6800，最低179.7500，成交量12798手。

　　報(bào)告日期2020年03月31日，年結(jié)日12-31，幣種美元，Mirati Therapeutics Inc.（MRTX）收入26.70萬，收入增長-78.54%，毛利26.70萬，毛利增長-78.54%，歸母凈利潤-8665.50萬，歸母凈利潤增長-111.81%，基本每股收益-2.02，稀釋每股收益-2.02，銷售毛利率100%，銷售凈利率-3.25%。

　　Mirati Therapeutics Inc.（MRTX）2020年01月01日至2020年03月31日License and collaboration revenues金額（USD）26.70萬，比率100%。

　　Mirati Therapeutics Inc.（MRTX）主要指標(biāo)（幣種：美元）：截止2020年03月31日Mirati Therapeutics Inc.（MRTX）市盈率（TTM）-29.5805255515749，市凈率（MRQ）7.62481989147032，每股收益（TTM）-5.93456817738442，每股凈資產(chǎn)15.036420745919，每股股息（USD）--，周息率--%，收入總額26.70萬，收入總額同比-78.5369774919614%，歸母凈利潤-8665.50萬，歸母凈利潤同比-111.808271411811%，毛利率100%，凈利率-32455.0561797753%，總股本4364.24萬，總市值（USD）50.04億。

　　報(bào)告日期2020年03月31日，年結(jié)日12-31，幣種美元，Mirati Therapeutics Inc.（MRTX）凈資產(chǎn)收益率-16.69%，總資產(chǎn)凈利率-15.13%。

　　公司介紹： Mirati Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer. This approach is transforming the treatment of patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and migration. Company's precision oncology programs seek to treat the patients most likely to benefit from targeted oncology treatments and is driven by drugs that target very specific genetic mutations, directed by genomic tests that identify patients who carry those driver mutations. The company's immuno-oncology programs are novel small molecule drugs designed to enhance and expand the efficacy of checkpoint inhibitors when given in combination. In addition to clinical programs, company has an active discovery research program focused on novel oncology targets. The promise of these approaches includes potentially better patient outcomes, more efficient cancer treatment and faster drug development.

　　本站數(shù)據(jù)均為參考數(shù)據(jù)，不具備市場交易依據(jù)。